P. Johnson

发表

The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B.

P. Collins, R. Olmsted, P. Johnson, 1990, The Journal of general virology.

The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.

P. Collins, R. Olmsted, P. Johnson, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes.

P. Wright, P. Johnson, D. Karzon, 1985, Vaccine.

SIV from stump-tailed macaques: molecular characterization of a highly transmissible primate lentivirus.

P. Fultz, H. McClure, P. Johnson, 1992, Virology.

Multiple viral determinants contribute to pathogenicity of the acutely lethal simian immunodeficiency virus SIVsmmPBj variant

H. McClure, D. Anderson, P. Johnson, 1993, Journal of virology.

The chemistry of site-directed serology for HIV infections.

D. E. Parks, R. Lerner, R. Houghten, 1989, AIDS research and human retroviruses.

Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus.

P. Collins, R. Olmsted, P. Johnson, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Viral genetic determinants in SIVsmmPBj pathogenesis

Philip R. Johnson, H. McClure, P. Johnson, 1994, Journal of medical primatology.

Pathogenic diversity of simian immunodeficiency viruses.

P. Johnson, V. Hirsch, Vanessa M. Hirsch, 1994, Virus research.

Spontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virus

P. Johnson, V. Hirsch, W. London, 1994, Journal of virology.

Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

N. Haigwood, D. Montefiori, P. Johnson, 1992, Proceedings of the National Academy of Sciences of the United States of America.

A highly divergent proviral DNA clone of SIV from a distinct species of African green monkey.

A. Fomsgaard, J. Allan, P. Johnson, 1991, Virology.

The simian immunodeficiency virus (SIV) rev gene regulates env expression.

P. Hung, P. Johnson, S. Lee, 1990, Journal of medical primatology.

Molecular clones of SIVsm and SIVagm: experimental infection of macaques and African green monkeys.

A. Fomsgaard, P. Johnson, V. Hirsch, 1990, Journal of medical primatology.

Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses.

R. Purcell, R. Olmsted, P. Johnson, 1989, Proceedings of the National Academy of Sciences of the United States of America.

SIV adaption to human cells

P. Johnson, M. Murphey-Corb, V. Hirsch, 1989, Nature.

Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression.

R. Chen, P. Johnson, T. Sferra, 1999, Human gene therapy.

Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum.

J. Yewdell, J. Bennink, L. Eisenlohr, 1990, Science.

Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses.

Philip R. Johnson, K. Clark, P. Johnson, 1999, Human gene therapy.

Gene delivery of vaccines for infectious disease.

K. Clark, P. Johnson, 2001, Current opinion in molecular therapeutics.

Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression.

R. Chen, K. Clark, P. Johnson, 1999, Journal of drug targeting.

Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse.

Philip R. Johnson, K. Clark, P. Johnson, 2000, Human gene therapy.

Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus

K. Clark, P. Johnson, X. Liu, 1999, Gene Therapy.

Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle.

Philip R. Johnson, K. Clark, P. Johnson, 1997, Human gene therapy.

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine.

P. Wright, P. Johnson, J. Thompson, 1986, The Journal of infectious diseases.

In vitro production of anti-influenza virus antibody after simultaneous administration of H3N2 and H1N1 cold-adapted vaccines in seronegative children.

K. Edwards, P. Wright, P. Johnson, 1986, Vaccine.

Gene transfer to the intestinal tract: a new approach using selective injection of the superior mesenteric artery.

P. Johnson, T. Sferra, D. McNeely, 1997, Human gene therapy.

Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines.

Philip R. Johnson, R. Chen, K. Clark, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Molecular cloning of feline immunodeficiency virus.

R. Purcell, R. Olmsted, P. Johnson, 1989, Proceedings of the National Academy of Sciences of the United States of America.

SIV adaptation to human cells.

P. Johnson, M. Murphey-Corb, V. Hirsch, 1989, Nature.

Frequency of broviac catheter infections in pediatric oncology patients.

W. Schaffner, K. Edwards, M. Decker, 1986, The Journal of infectious diseases.

Management of catheter-related bacteremia.

M. Decker, P. Johnson, 1988, The Pediatric infectious disease journal.

Vitamin B12 deficiency in an infant strictly breast-fed by a mother with latent pernicious anemia.

P. Johnson, J. Roloff, 1982, The Journal of pediatrics.

Comparison of long‐term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine

P. Wright, P. Johnson, S. Feldman, 1985, Journal of medical virology.

Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival

N. Haigwood, J. Ranchalis, P. Johnson, 1997, Journal of virology.

Animal models for acquired immunodeficiency syndrome.

T. Kindt, P. Johnson, S. Sawasdikosol, 1992, Advances in immunology.

Developing animal models for AIDS research--progress and problems.

P. Johnson, A. Lewis, 1995, Trends in biotechnology.

Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector.

P. Johnson, S. Chatterjee, K. Wong, 1992, Science.

The A and B subgroups of human respiratory syncytial virus: comparison of intergenic and gene-overlap sequences.

P. Collins, P. Johnson, 1988, The Journal of general virology.

The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro.

P. Collins, P. Johnson, M. Hill, 1990, The Journal of general virology.

Simian immunodeficiency virus infection of macaques: end-stage disease is characterized by widespread distribution of proviral DNA in tissues.

P. Johnson, V. Hirsch, P. Zack, 1991, The Journal of infectious diseases.

Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.

D. Montefiori, P. Johnson, V. Hirsch, 1994, Virology.

A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.

K. Clark, P. Johnson, F. Voulgaropoulou, 1996, Gene therapy.

Cell lines for the production of recombinant adeno-associated virus.

Philip R. Johnson, K. Clark, P. Johnson, 1995, Human gene therapy.

Species-specific diversity among simian immunodeficiency viruses from African green monkeys

M. Taylor, G. Shaw, B. Hahn, 1991, Journal of virology.

Transfer of the feline erythropoietin gene to cats using a recombinant adeno-associated virus vector

P. Johnson, C. J. Beall, P. Stromberg, 2000, Gene Therapy.

Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication

P. Johnson, Charles Brown, V. Hirsch, 1995, Journal of virology.

A distinct African lentivirus from Sykes' monkeys

R. Lenroot, G. Myers, P. Fultz, 1993, Journal of virology.

The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques.

P. Johnson, V. Hirsch, S. Goldstein, 1991, Virology.

Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine.

D. Montefiori, P. Johnson, V. Hirsch, 1994, The Journal of infectious diseases.

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

N. Haigwood, N. Letvin, J. Ranchalis, 1996, Immunology letters.

The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness.

P. Collins, P. Johnson, 1988, The Journal of general virology.

Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

B. Moss, R. Chanock, B. Murphy, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

H. Wakimoto, E. Chiocca, D. Knipe, 2003, Gene Therapy.

Detection of SIV antigens by HIV-1 antigen capture immunoassays.

R. Olmsted, P. Johnson, R. Engle, 1990, Journal of Acquired Immune Deficiency Syndromes.

Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques

D. Montefiori, P. Johnson, W. Robinson, 1990, Journal of virology.

Cloning and sequences of primate CD4 molecules: Diversity of the cellular receptor for simian immunodeficiency virus/human immunodeficiency virus

A. Fomsgaard, P. Johnson, V. Hirsch, 1992, European journal of immunology.

Simian immunodeficiency viruses from African green monkeys display unusual genetic diversity

A. Fomsgaard, J. Allan, R. Olmsted, 1990, Journal of virology.

A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.

Philip R. Johnson, M. Caligiuri, K. Pfeffer, 1999, Journal of immunology.

Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells.

N. Haigwood, D. Montefiori, P. Johnson, 1992, AIDS research and human retroviruses.

Genetic variation of simian immunodeficiency viruses in nonhuman primates.

P. Johnson, V. Hirsch, 1992, AIDS research and human retroviruses.

Molecular characterization of SIV in tissues from experimentally infected macaques.

P. Johnson, V. Hirsch, P. Zack, 1990, Journal of medical primatology.

Identification of a new subgroup of SIVagm in tantalus monkeys.

P. Johnson, A. Ogen-Odoi, V. Hirsch, 1993, Virology.

SIV infection of macaques as a model for AIDS pathogenesis.

P. Johnson, V. Hirsch, V M Hirsch, 1992, International reviews of immunology.

Optimising genetic potential for wool production and quality through maternal nutrition

Sue Hatcher, P. R. Johnson, S. Hatcher, 2005 .

The 1B (NS2), 1C (NS1) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSV genomic RNA.

P. Collins, P. Johnson, Peter L. Collins, 1989, The Journal of general virology.

Failure of intraventricular gamma globulin to eradicate echovirus encephalitis in a patient with X-linked agammaglobulinemia.

K. Edwards, P. Wright, P. Johnson, 1985, The New England journal of medicine.

E. Walsh, B. Murphy, D. Alling, 1987, Journal of virology.

Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus.

R. Webster, P. Roberson, P. Wright, 1985, The Journal of infectious diseases.

Sequence comparison of the phosphoprotein mRNAs of antigenic subgroups A and B of human respiratory syncytial virus identifies a highly divergent domain in the predicted protein.

P. Collins, P. Johnson, 1990, The Journal of general virology.

Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates.

D. Montefiori, P. Johnson, W. Robinson, 1990, Journal of medical primatology.

Coexpression of biologically active simian immunodeficiency virus (SIV) Rev and Env in an SV40 system: the SIV rev gene regulates env expression.

P. Hung, P. Johnson, S. Lee, 1990, Virology.

Molecular characterization of simian lentiviruses from east African green monkeys.

A. Fomsgaard, J. Allan, P. Johnson, 1990, Journal of medical primatology.

Molecular diversity of SIVsmm/PBj and a cognate variant, SIVsmm/PGg.

H. McClure, P. Johnson, V. Hirsch, 1991, Journal of medical primatology.

Selective infection of human CD4+ cells by simian immunodeficiency virus: productive infection associated with envelope glycoprotein-induced fusion.

R. Purcell, A. Fauci, S. Koenig, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Antibodies to the putative SIV infection‐enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques

Philip R. Johnson, M. Gardner, P. Johnson, 1995, AIDS.

Receptor function of CD4 structures from African green monkey and pig-tail macaque for simian immunodeficiency virus, SIVsm, SIVagm, and human immunodeficiency virus type-1.

J. Hansen, A. Fomsgaard, P. Johnson, 1995, Viral immunology.